261 Secukinumab 150 Mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis with High Retention Rate: 4-Year Results from the Phase 3 Trial, MEASURE 2
Rheumatology（2019）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要